Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes [version 1; peer review: 5 approved]
Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that ov...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2020-07-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/9-827/v1 |